阿司匹林或其他非甾体抗炎药的维持使用与前列腺癌风险
瑞典全国性人群队列研究纳入长期使用阿司匹林(n=419,931)或NSAIDs(n=223,437)的成年男性,随访至首次癌症诊断、死亡或2012年12月31日。结果显示阿司匹林总体SIR=0.87(95%CI 0.85-0.88),使用≥5年SIR=0.31(95%CI 0.30-0.32);其他NSAIDs总体SIR=0.87(95%CI 0.85-0.90),使用≥3年SIR=0.58(95%CI 0.53-0.63)。排除他汀使用者后,阿司匹林与前列腺癌风险无剩余关联(SIR=0.99,95%CI 0.96-1.02),但≥5年使用者SIR=0.31(95%CI 0.29-0.34);非阿司匹林NSAIDs保护效应仍存在(SIR=0.92,95%CI 0.88-0.95)。
要点
- 阿司匹林维持使用与前列腺癌风险降低相关,尤其使用≥5年者。
- 其他NSAIDs使用与前列腺癌风险降低相关,使用≥3年者更明显。
- 排除他汀使用者后,阿司匹林总体关联消失,但≥5年使用仍相关。
核心结论
- 基于人群的队列研究提供证据表明阿司匹林和其他NSAIDs对前列腺癌有保护作用,尤其使用时间较长者;但合并使用他汀强烈影响阿司匹林使用者的风险。
研究设计与样本
- 瑞典全国性基于人群的队列研究,纳入所有长期(≥180天)成年男性阿司匹林使用者(n=419,931)或NSAIDs使用者(n=223,437),从首次配药日期随访至首次癌症诊断、死亡或2012年12月31日。
主要发现
- 阿司匹林总体SIR=0.87(95%CI 0.85-0.88),使用≥5年SIR=0.31(95%CI 0.30-0.32)。
- 其他NSAIDs使用者总体SIR=0.87(95%CI 0.85-0.90),使用≥3年SIR=0.58(95%CI 0.53-0.63)。
- 排除他汀使用者后,阿司匹林与前列腺癌无剩余关联(SIR=0.99,95%CI 0.96-1.02),但使用≥5年者SIR=0.31(95%CI 0.29-0.34)。
- 非阿司匹林NSAIDs使用者排除他汀使用者后保护效应仍存在(SIR=0.92,95%CI 0.88-0.95)。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) may have a preventive effect against prostate cancer. However, evidence is limited and still controversial, especially considering non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs). METHODS: Swedish nationwide population-based cohort study including all long-term (≥180 days) adult male users of aspirin (n = 419,931) or NSAIDs (n = 223,437) followed from the first dispense date until the first cancer diagnosis, death or 31 December 2012, whichever occurred first. The risk of prostate cancer was measured as standardized incidence ratios (SIR) and 95% confidence intervals (CI), assessing duration of use, age and concomitant statins intake, comparing to the general male background population of the same age in Sweden. RESULTS: The overall SIR suggests that maintenance use of aspirin decreases the risk of prostate cancer (SIR = 0.87, 95% CI 0.85-0.88), in particular if used ≥5 years (SIR = 0.31, 95% CI 0.30-0.32). The overall risk was decreased (SIR = 0.87, 95% CI 0.85-0.90) among other NSAIDs users, and again in particular among longer-term users (≥3 years) with SIR = 0.58 (95% CI 0.53-0.63). When statins users were excluded from all aspirin users, there was no remaining association with prostate cancer (SIR = 0.99, 95% CI 0.96-1.02), only if taken ≥5 years (SIR = 0.31, 95% CI 0.29-0.34). For non-aspirin NSAIDs users, the protective effect remained after exclusion of statins users (SIR = 0.92, 95% CI 0.88-0.95). CONCLUSIONS: This population-based cohort study provides evidence for a protective effect of aspirin and other NSAIDs against prostate cancer, in particular for longer durations of use, yet concomitant use of statins strongly influences the risk among aspirin users.
引用
- Ma Y, Brusselaers N. Maintenance use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk. Prostate Cancer Prostatic Dis. 2017. PMID: 29259292. doi:10.1038/s41391-017-0021-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。